...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Modern rheumatology >Guidance on using tocilizumab for juvenile idiopathic arthritis
【24h】

Guidance on using tocilizumab for juvenile idiopathic arthritis

机译：托西珠单抗治疗青少年特发性关节炎的指南

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Medical care for rheumatic disease in children has been supported by advances in rheumatology. In the past few years and based on knowledge about cytokines, particularly marked advances have been made in treatments using biological products. The fact that patients showed a marked response to treatment with biological products also provided uniform direction to treatment choice, which had previously been chaotic. On the other hand, biological products inhibit the action of physiologically essential substances, such as inflammatory cytokines or their receptors. This led to concerns about the risk of fatal or life-threatening adverse reactions, and rheumatologists are now required to take a disciplined approach to the use of these products. Thus, we sincerely hope that this guidance on using tocilizumab for juvenile idiopathic arthritis serves as a desk reference for pediatric rheumatologists and other healthcare professionals treating children with rheumatic diseases by biological drugs.
机译：风湿病学的发展为儿童风湿病的医疗提供了支持。在过去的几年中，基于对细胞因子的了解，在使用生物产品进行治疗方面取得了特别明显的进步。患者对生物产品的治疗表现出明显的反应，这一事实也为治疗选择提供了统一的方向，而这种治疗以前是混乱的。另一方面，生物制品抑制生理必需物质的作用，例如炎性细胞因子或其受体。这引起了对致命或威胁生命的不良反应风险的担忧，现在，风湿病医生被要求对这些产品的使用采取严格的方法。因此，我们衷心希望，本使用托西珠单抗治疗幼年特发性关节炎的指南可为小儿风湿病学家和其他使用生物药物治疗风湿性疾病的医疗保健专业人员提供参考。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号